- Home
- IGMS vs JNVR Comparison
IGMS vs JNVR Comparison
Compare IGMS & JNVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- JNVR
- Stock Information
- Founded
- IGMS 1993
- JNVR 2018
- Country
- IGMS United States
- JNVR United States
- Employees
- IGMS N/A
- JNVR N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- JNVR Finance: Consumer Services
- Sector
- IGMS Health Care
- JNVR Finance
- Exchange
- IGMS Nasdaq
- JNVR Nasdaq
- Market Cap
- IGMS 82.1M
- JNVR 93.3M
- IPO Year
- IGMS 2019
- JNVR 2023
- Fundamental
- Price
- IGMS $1.13
- JNVR $63.99
- Analyst Decision
- IGMS Hold
- JNVR
- Analyst Count
- IGMS 8
- JNVR 0
- Target Price
- IGMS $6.14
- JNVR N/A
- AVG Volume (30 Days)
- IGMS 155.8K
- JNVR 1.9M
- Earning Date
- IGMS 05-20-2025
- JNVR 05-13-2025
- Dividend Yield
- IGMS N/A
- JNVR N/A
- EPS Growth
- IGMS N/A
- JNVR N/A
- EPS
- IGMS N/A
- JNVR N/A
- Revenue
- IGMS $2,679,000.00
- JNVR $2,099,660.00
- Revenue This Year
- IGMS $121.76
- JNVR N/A
- Revenue Next Year
- IGMS $46.83
- JNVR N/A
- P/E Ratio
- IGMS N/A
- JNVR N/A
- Revenue Growth
- IGMS 25.77
- JNVR 4.82
- 52 Week Low
- IGMS $0.92
- JNVR $3.37
- 52 Week High
- IGMS $22.50
- JNVR $91.38
- Technical
- Relative Strength Index (RSI)
- IGMS 39.53
- JNVR 57.60
- Support Level
- IGMS $1.11
- JNVR $64.09
- Resistance Level
- IGMS $1.40
- JNVR $91.38
- Average True Range (ATR)
- IGMS 0.11
- JNVR 14.99
- MACD
- IGMS -0.01
- JNVR -0.59
- Stochastic Oscillator
- IGMS 5.56
- JNVR 53.59
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About JNVR Janover Inc.
Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from platform fees and subscription revenue.